Results 301 to 310 of about 362,523 (334)

Prognostic Significance of Lung Immune Prognostic Index at Diagnosis in Stage III Non-Small Cell Lung Cancer. [PDF]

Curr Oncol
Eren T, Kavak EE, Dili İ, Zeynelgil E.
europepmc   +1 more source

LEAP-008: pembrolizumab plus lenvatinib after immunotherapy in non-small cell lung cancer. [PDF]

J Thorac Dis
Fukuda K.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

NSCLC

Onkologische Welt, 2023
Nach Daten der Studie FLAURA2 zeigt Osimertinib plus Chemotherapie in der Behandlung des nicht-kleinzelligen Lungenkarzinoms (NSCLC) einen statistisch signifikanten Vorteil beim progressionsfreien Überleben (PFS) im Vergleich zu Osimertinib allein. Studienleiter Dr. Pasi Jänne, Boston (USA), stellte die Ergebnisse der Studie vor.
openaire   +1 more source

Resektables NSCLC

Onkologische Welt, 2023
Mittlerweile sind synergistische Effekte bei Kombination von Immuntherapie und Angiogenesehemmung in der Behandlung des nicht-kleinzelligen Lungenkarzinoms (NSCLC) bekannt. Das bestätigt die Phase-III-Studie EAST ENERGY, in der das Regime Pembrolizumab/Ramucirumab zu einer hohen Rate pathologischer Remissionen und R0-Resektionen führte.
openaire   +1 more source

Cemiplimab (Libtayo) for NSCLC

The Medical Letter on Drugs and Therapeutics, 2023
The FDA has approved cemiplimab-rwlc (Libtayo – Regeneron), an immune checkpoint inhibitor, for use in combination with platinum-based chemotherapy for first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults with no epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or ROS1 aberrations
openaire   +2 more sources

Capmatinib (Tabrecta) for NSCLC

The Medical Letter on Drugs and Therapeutics, 2023
The FDA has granted regular approval to the oral kinase inhibitor capmatinib (Tabrecta – Novartis) for treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping. MET exon 14 skipping mutations occur in 3-4% of NSCLC cases.
openaire   +2 more sources

Prognosis in N2 NSCLC

Lung Cancer, 2004
The prognosis of bronchogenic carcinoma in stage III N2 is poor. Five-year survival ranges between 0 and 5%. Lymph-node involvement itself still is the main prognostic factor. Complete lymphadenectomy improves long-term survival in contrast to lymph-node sampling.
Godehard, Friedel, Volker, Steger, Thomas, Kyriss, Jutta, Zoller, Heikki, Toomes   +4 more
openaire   +2 more sources

Sotorasib (Lumakras) for NSCLC

The Medical Letter on Drugs and Therapeutics, 2023
Sotorasib (Lumakras — Amgen), an oral KRAS inhibitor, has received accelerated approval by the FDA for treatment of KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults who received at least one prior systemic therapy.
openaire   +2 more sources

Multimodality Therapy for NSCLC

2016
The standard therapy for patients with unrespectable stage III non-small-cell lung cancer (NSCLC) is the combination of chemotherapy and radiotherapy. Although the concurrent use of both treatment modalities has been shown to be superior to sequential therapy, the role for additional chemotherapy, either as induction or as consolidation, remains ...
Lingling, Du, Saiama N, Waqar, Daniel, Morgensztern   +2 more
openaire   +2 more sources

Mutations in NSCLC.

Journal of Clinical Oncology, 2014
e18516 Background: Lung cancer has a poor prognosis, with 15-20% five-years survival rate. However, lung cancer treatment has in the last years taken advantage of newly developed targeted therapies...
Åslaug Helland, Odd Terje Brustugun, Sigve Nakken, Ann Rita Halvorsen, Jinchang Sun, Susanne. Lorenz, Daniel Vodak, Ola Myklebost, Eivind Hovig, Leonardo A. Meza-Zepeda   +9 more
openaire   +1 more source